Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs

References

• Pappachan JM, Babu S, Krishnan B, et al. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol. 2017;5(4):384–393. Available from: http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=1&id=10.14218%2FJCTH.2017.00013
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Wong VWS, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1:1–22.
   Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9:715–732.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23:6571–6592.
   PubMed Web of Science ®Google Scholar
• Zheng D, Wang X, Antonson P, et al. Genomics of sex hormone receptor signaling in hepatic sexual dimorphism. Mol Cell Endocrinol. 2016;1–9. doi:10.1016/j.mce.2017.05.025
   Web of Science ®Google Scholar
• Lorbek G, Urlep Ž, Rozman D. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics. Internet. 2016;17:1273–1288. Available from http://www.ncbi.nlm.nih.gov/pubmed/27377717
   PubMed Web of Science ®Google Scholar
• Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645–655.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465.
   PubMed Web of Science ®Google Scholar
• Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324.
   Google Scholar
• Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentratios of liver enzymes in plasma. Nat Genet. 2012;43:1131–1138.
   Web of Science ®Google Scholar
• Hsu S-H, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871–2883. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22820288%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3408748
   PubMed Web of Science ®Google Scholar
• Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015;7:1–11.
   PubMed Web of Science ®Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68:268–279.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
   PubMed Web of Science ®Google Scholar
• Lim HW, Bernstein DE. Risk factors for the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including genetics. Clin Liver Dis. 2018;22:39–57.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291–1326.
   PubMed Web of Science ®Google Scholar
• Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274–283.
   PubMedGoogle Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Ohbora A, et al. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237–243.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA a cancer. J Clin. 2015;65:87–108.
   Google Scholar
• Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:474–485.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164. DOI:10.1001/archinte.164.19.2169
   Google Scholar
• Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319–327.
   PubMed Web of Science ®Google Scholar
• Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40:745–752.
   PubMed Web of Science ®Google Scholar
• Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593–1602.
   PubMed Web of Science ®Google Scholar
• Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol. 2015;50:341–346. Available from http://www.tandfonline.com/doi/full/10.3109/00365521.2014.983160
   PubMed Web of Science ®Google Scholar
• Day CP, James OFW. Steatohepatitis: A Tale of Two “Hits”? Gastroenterology. 1998;114:842–845.
   PubMed Web of Science ®Google Scholar
• Eguchi Y, Eguchi T, Mizuta T, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462–469.
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–1048.
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.
   PubMed Web of Science ®Google Scholar
• Gambino R, Cassader M, Pagano G, et al. Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology. 2007;45:1097–1107.
   PubMed Web of Science ®Google Scholar
• Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–1524. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996054/
   PubMed Web of Science ®Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–735.
   PubMed Web of Science ®Google Scholar
• Cao SS, Kaufman RJ. Targeting endoplasmic reticulum stress in metabolic disease. Expert Opin Ther Targets. 2013;17:437–448.
   PubMed Web of Science ®Google Scholar
• Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr Hepatol Reports. 2016;15:134–139.
   PubMedGoogle Scholar
• Das K, Chowdhury A. Lean -NASH: distinctiveness and clinical implication. Hepatol Int. 2013;7:S806–S813.
   PubMedGoogle Scholar
• Dela Cruz AC, Bugianesi E, George J, et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:S–909.
   Web of Science ®Google Scholar
• Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016;45:639–652.
   PubMed Web of Science ®Google Scholar
• Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36–44.
   PubMed Web of Science ®Google Scholar
• Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease—a starter’s guide. Nutrients. 2017;9:1–13.
   Web of Science ®Google Scholar
• Lorbek G, Perše M, Jeruc J, et al. Lessons from hepatocyte-specific Cyp51 knockout mice: impaired cholesterol synthesis leads to oval cell-driven liver injury. Sci Rep. 2015;5:1–11.
   Web of Science ®Google Scholar
• Ng MK, Jessup W, Celermajer DS. Sex-related differences in the regulation of macrophage cholesterol metabolism. Curr Opin Lipidol. 2001;12:505–510.
   PubMed Web of Science ®Google Scholar
• Wang SH, Yeh SH, Lin WH, et al. Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B. Hepatology. 2009;50:1392–1402.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim SH, Kim S, et al. Sex-specific metabolic interactions between liver and adipose tissue in MCD diet-induced non-alcoholic fatty liver disease. 2016;7(30):46959–46971
   Google Scholar
• Wauthier V, Waxman DJ. Sex-specific early growth hormone response genes in rat liver. Mol Endocrinol. 2008;22:1962–1974.
   PubMedGoogle Scholar
• Ling G, Sugathan A, Mazor T, et al. Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol. 2010;30:5531–5544.
   PubMed Web of Science ®Google Scholar
• Waxman DJ, O’Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20:2613–2629.
   PubMed Web of Science ®Google Scholar
• Justo R, Boada J, Frontera M, et al. Gender dimorphism in rat liver mitochondrial oxidative metabolism and biogenesis. Am J Cell Physiol. 2005;289:372–378.
   PubMed Web of Science ®Google Scholar
• Lorbek G, Perše M, Horvat S, et al. Sex differences in the hepatic cholesterol sensing mechanisms in mice. Molecules. 2013;18:11067–11085.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015;402:113–119.
   PubMed Web of Science ®Google Scholar
• Tao Z, Zheng LD, Smith C, et al. Estradiol signaling mediates gender difference in visceral adiposity via autophagy. Cell Death Dis. 2018;9:309.
   PubMed Web of Science ®Google Scholar
• Camhi SM, Bray GA, Bouchard C, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity. 2011;19:402–408.
   PubMed Web of Science ®Google Scholar
• Lichanska AM, Waters MJ. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet. 2008;24:41–47.
   PubMed Web of Science ®Google Scholar
• Chia DJ. Minireview: mechanisms of growth hormone-mediated gene regulation. Mol Endocrinol. 2014;28:1012–1025.
   PubMedGoogle Scholar
• MacLeod JN, Pampori NA, Shapiro BH. Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrinol. 1991;131:395–399.
   PubMed Web of Science ®Google Scholar
• Oshida K, Waxman DJ, Corton JC. Chemical and hormonal effects on STAT5b-dependent sexual dimorphism of the liver transcriptome. PLoS One. 2016;11:1–24.
   Web of Science ®Google Scholar
• Baik M, Nam YS, Piao MY, et al. Liver-specific deletion of the signal transducer and activator of transcription 5 gene aggravates fatty liver in response to a high-fat diet in mice. J Nutr Biochem. 2016;29:56–63.
   PubMed Web of Science ®Google Scholar
• Chishima S, Kogiso T, Matsushita N, et al. The relationship between the growth hormone/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease. Intern Med. 2017;56:473–480. Available from: https://www.jstage.jst.go.jp/article/internalmedicine/56/5/56_56.7626/_article
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34:309–338.
   PubMed Web of Science ®Google Scholar
• Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett. 2015;356:231–243.
   PubMed Web of Science ®Google Scholar
• Chen KL, Madak-Erdogan Z. Estrogens and female liver health. Steroids. 2017. DOI:10.1016/j.steroids.2017.10.015
   Web of Science ®Google Scholar
• Mintziori G, Poulakos P, Tsametis C, et al. Hypogonadism and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:145–150.
   PubMed Web of Science ®Google Scholar
• Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol. 2015;2015:294278.
   PubMed Web of Science ®Google Scholar
• Iorga A, Cunningham CM, Moazeni S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33.
   PubMed Web of Science ®Google Scholar
• Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. 2017;1043:227–256.
   Google Scholar
• Barros RPA, Gustafsson JÅ. Estrogen receptors and the metabolic network. Cell Metab. 2011;14:289–299.
   PubMed Web of Science ®Google Scholar
• Xu Y, Nedungadi TP, Zhu L, et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab. 2011;14:453–465.
   PubMed Web of Science ®Google Scholar
• Frank A, Brown LM, Clegg DJ. The role of hypothalamic estrogen receptors in metabolic regulation. Front Neuroendocrinol. 2014;35:550–557.
   PubMed Web of Science ®Google Scholar
• Adolph TE, Grander C, Grabherr F, et al. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8):E1649.
   Web of Science ®Google Scholar
• Chen Z, Yu R, Xiong Y, et al. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16:1–9.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42:1175–1183.
   PubMed Web of Science ®Google Scholar
• Böttner A, Kratzsch J, Müller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004;89:4053–4061.
   PubMed Web of Science ®Google Scholar
• Mody A, White D, Kanwal F, et al. Relevance of low testosterone to nonalcoholic fatty liver disease. Cardiovasc Endocrinol. 2015;4:83–89. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01626549-201509000-00003
   PubMed Web of Science ®Google Scholar
• Kim S, Kwon H, Park J-H, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–1041.
   PubMed Web of Science ®Google Scholar
• Tsai EC, Boyko EJ, Leonetti DL, et al. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord. 2000;24:485–491.
   PubMed Web of Science ®Google Scholar
• Kovac U, Rozman D. Genetics of non-alcoholic fatty liver disease. eLS. 2015:1–8. DOI:10.1002/9780470015902.a0025335
   Google Scholar
• Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128–146.
   PubMed Web of Science ®Google Scholar
• Wei JL, Leung JC-F, Loong TC-W, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110:1306–1314.
   PubMed Web of Science ®Google Scholar
• Adams LA, Marsh JA, Ayonrinde OT, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. J Gastroenterol Hepatol. 2012;27:1520–1527.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Bo S, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 2013;62:1109–1120.
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014;46:352–356.
   PubMed Web of Science ®Google Scholar
• Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol. 2015;7:226–234.
   PubMed Web of Science ®Google Scholar
• Blagotin K, Rozman D. Targeting signalling pathways in hepatocellular carcinoma. Curr Pharm Des. 2017;23(1):170–175.
   Google Scholar
• DiStefano JK, Gerhard GS. Circulating microRNAs in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2017;106:201–207.
   Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F, Adibi P, Rafiei R, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–843.
   PubMed Web of Science ®Google Scholar
• Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology. 2011;54:1610–1619.
   PubMed Web of Science ®Google Scholar
• Salomone F, Godos J, Zelber-Sagi S. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver Int. 2016;36:5–20.
   PubMed Web of Science ®Google Scholar
• Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–2096.
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Brooks DG, Chaplin D, et al. Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. J Pers Med. 2012;158–174.
   PubMedGoogle Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet. 2010;376(9756):1916–1922.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Hamasaki K, Ishikawa H, et al. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut. 2003;52:914. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773673/
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Iida K, Takahashi K, et al. Growth Hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132:938–943.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Fukuoka H, Iguchi G, et al. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency. Growth Horm IGF Res. 2014;24:174–179.
   PubMed Web of Science ®Google Scholar
• Fisher CP, Kierzek AM, Plant NJ, et al. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15070–15078.
   PubMed Web of Science ®Google Scholar
• Kolodkin A, Boogerd FC, Plant N, et al. Emergence of the silicon human and network targeting drugs. Eur J Pharm Sci. 2012;46:190–197. Internet.
   PubMed Web of Science ®Google Scholar
• Cvitanović T, Reichert MC, Moškon M, et al. Large-scale computational models of liver metabolism: how far from the clinics? Hepatology. 2017;66:1323–1334.
   PubMed Web of Science ®Google Scholar
• Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43:317–334.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013;8:1–12.
   Web of Science ®Google Scholar
• Zhou S-F, Yang L-P, Wei M, et al. Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2. Curr Drug Metab. 2009;10:713–729. Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-2002&volume=10&issue=7&spage=713
   PubMed Web of Science ®Google Scholar
• Fisher CDC, Lickteig AJA, Augustine LML, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087–2094. Available from: http://dmd.aspetjournals.org/content/37/10/2087.short
   PubMed Web of Science ®Google Scholar
• Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Current Drug Metabolism. 2009;10:567–578.
   PubMed Web of Science ®Google Scholar
• Kohjima M, Enjoji M, Higuchi N, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007;20:351–358.
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Jimenez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos. 2006;34:1556–1562.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJG, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39:159–234.
   PubMed Web of Science ®Google Scholar